The development of atopic dermatitis is independent of Immunoglobulin E up‐regulation in the K14‐IL‐4 SKH1 transgenic mouse model

Chen, Lin; Overbergh, Lutgart; Mathieu, Chantal; Chan, Lawrence S.

doi:10.1111/j.1365-2222.2008.02987.x

Cited by 26 publications

(16 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genetically, AD has been shown to be associated with IL-4 and IL-13 polymorphisms, 45–48 and eczema-like features can be induced in transgenic mice overexpressing these cytokines. 49–52 In humans, mRNA in situ hybridization studies by Hamid et al demonstrated increased levels of IL-4 and IL-13 in both acute and chronic AD, to a higher degree than IFN-γ. 26,53 IL-4 decreases the expression of multiple genes in the epidermal differentiation complex (EDC) that regulate epidermal barrier function.…”

Section: The Emerging Immune Map Of Admentioning

confidence: 99%

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

Brunner

Guttman‐Yassky

Leung

2017

Journal of Allergy and Clinical Immunology

504

461

View full text Add to dashboard Cite

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of Th22, Th17/IL-23 and Th1 cytokine pathways, depending on the subtype of the disease. In this review, we discuss our current understanding of the AD immune map in both early-onset as well as chronic disease. Clinical studies using broad and targeted therapeutics have helped to elucidate the contribution of various immune axes to the disease phenotype. Importantly, immune activation extends well beyond lesional AD, as non-lesional skin and the blood component harbor AD-specific inflammatory changes. For this reason, future therapeutics will need to focus on a systemic treatment approach, especially in patients suffering from moderate-to-severe disease.

show abstract

Section: The Emerging Immune Map Of Admentioning

confidence: 99%

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

Brunner

Guttman‐Yassky

Leung

2017

Journal of Allergy and Clinical Immunology

504

461

View full text Add to dashboard Cite

show abstract

“…Generation of a variant of this IL-4 transgenic mouse (on the SKH1 hairless mouse background) yielded an IL-4 transgenic where IgE levels did not increase. However all the other markers of AD were comparable to the transgenic mice on the CByB6 background [88]. When the IL-4 transgenic was backcrossed to pro-Th2 Balb/c or pro-Th1 C57Bl/6 backgrounds, the Balb/c mice developed more severe AD than the C57Bl/6 mice, although the IgE levels were unchanged in the Balb/c but elevated in the C57Bl/6 strain [89].…”

Section: Th2 Cytokinesmentioning

confidence: 99%

Th2 Cytokines and Atopic Dermatitis

Brandt

Sivaprasad

2011

J Clin Cell Immunol

544

433

View full text Add to dashboard Cite

Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease, is increasing in prevalence around the world. Intensive research is ongoing to understand the mechanisms involved in the development of AD and offer new treatment options for patients suffering from AD. In this review, we highlight the importance of allergic Th2 responses in the development of the disease and summarize relevant literature, including genetic studies, studies of human skin and mechanistic studies on keratinocytes and mouse models of AD. We discuss the importance of the skin barrier and review recent findings on the pro-Th2 cytokines TSLP, IL-25, and IL-33, notably their ability to polarize dendritic cells and promote Th2 responses. After a brief update on the contribution of different T-cell subsets to AD, we focus on Th2 cells and the respective contributions of each of the Th2 cytokines (IL-4, IL-13, IL-5, IL-31, and IL-10) to AD. We conclude with a brief discussion of the current gaps in our knowledge and technical limitations.

show abstract

“…A non-IgE-associated AD model was regarded as a mode of human intrinsic AD [44]. In an animal model of AD, IL-18 contributes the spontaneous development of AD-like skin lesions independently of IgE [45].…”

Section: Animal Models For Intrinsic Admentioning

confidence: 99%

Extrinsic and intrinsic types of atopic dermatitis

Tokura

2010

Journal of Dermatological Science

304

249

View full text Add to dashboard Cite

The development of atopic dermatitis is independent of Immunoglobulin E up‐regulation in the K14‐IL‐4 SKH1 transgenic mouse model

Abstract: K14-IL-4-Tg/SKH1 mice developed skin inflammation that resembled human intrinsic atopic dermatitis. Therefore, this model may be suitable to study the pathogenesis of intrinsic atopic dermatitis.

Cited by 26 publications

References 58 publications

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

Th2 Cytokines and Atopic Dermatitis

Extrinsic and intrinsic types of atopic dermatitis

Contact Info

Product

Resources

About